PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known	
Application Number	09/869,414
Filing Date	June 27, 2001
First Named Inventor	Mark Gurney
Art Unit	1647
Examiner Name	C. ~~Nicholas~~ NICHOLS
Attorney Docket Number	29915/6280M

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SNS	A1	5,424,205	6/13/95	Dovey et al.	
	A2	5,593,846	1/14/97	Schenk et al.	
	A3	5,733,768	3/31/98	Dixon et al.	
	A4	5,744,346	4/28/98	Chrysler et al.	
	A5	5,750,349	5/12/98	Suzuki et al.	
	A6	5,766,846	6/16/98	Schlossmacher et al.	
	A7	5,837,672	11/17/98	Schenk et al.	
	A8	5,849,560	12/15/98	Abraham	
	A9	5,942,400	8/24/99	Anderson et al.	
	A10	6,025,180	2/15/00	Powell et al.	
	A11	5,455,169	10/3/95	Mullan	
	A12	5,795,963	8/18/98	Mullan	
	A13	5,877,015	3/2/99	Hardy et al.	
	A14	6,211,428	4/3/01	Singh et al.	
	A15	6,221,645	4/24/01	Chryster et al.	
	A16	6,245,884	6/12/01	Hook	
	A17	6,245,964	6/12/01	McLonlogue et al.	
	~~A18~~	~~60/141,363~~		~~Lin et al.~~	
	~~A19~~	~~60/168,060~~		~~Lin et al.~~	
	~~A20~~	~~60/178,368~~		~~Lin et al.~~	
	~~A21~~	~~60/210,292~~		~~Hong et al.~~	
	~~A22~~	~~09/277,229~~		~~Citron et al.~~	
	A23	6,313,268		Hook	
	~~A24~~	~~60/177,836~~		~~Lin et al.~~	
	~~A25~~	~~60/119,671~~		~~Basi et al.~~	
	~~A26~~	~~60/139,172~~		~~Andersen et al.~~	
	~~A27~~	~~60/114,408~~		~~Basi et al.~~	
	~~A28~~	~~09/404,578~~		~~Chrysler et al.~~	
	~~A29~~	~~09/054,334~~		~~Anderson et al.~~	
	~~A30~~	~~09/730,329~~		~~Anderson et al.~~	
	~~A31~~	~~09/471,669~~		~~Anderson et al.~~	
	~~A32~~	~~09/501,700~~		~~Anderson et al~~	
	~~A33~~	~~09/723,722~~		~~Anderson et al.~~	
	~~A34~~	~~09/724,566~~		~~Anderson et al.~~	
	~~A35~~	~~09/723,730~~		~~Anderson et al.~~	
CN	~~A36~~	~~09/724,571~~		~~Anderson et al.~~	

CONSIDERED NOT PRINT.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	09/869,414
Filing Date	June 27, 2001
First Named Inventor	Mark Gurney
Art Unit	1647
Examiner Name	C. ~~Nicholas~~ NICHOLS
Attorney Docket Number	29915/6280M

CGN	A37	~~09/724,568~~	~~—~~	~~Anderson et al.~~	~~—~~
	A38	~~09/724,569~~	~~—~~	~~Anderson et al.~~	~~—~~
	A39	6,319,689	—	Powell et al.	—
	A40	6,162,630	12/19/00	Powell et al.	—
	A41	6,319,689	11/20/01	Powell et al.	—
	A42	6,358,725	3/19/02	Christie at al.	—
	A43	6,361,975	3/26/02	Christie et al.	—
	A44	6,291,223	9/18/01	Christie et al.	—
CGN	A45	6,545,127	4/08/03	Tang et al.	—

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
CGN	B1	WO 96/31122	10/10/96	Dixon et al.	—	
	B2	WO 96/40885	12/19/96	Chrysler et al.	—	
	B3	WO 98/13488	4/2/98	Dyrks et al.	—	
	B4	WO 98/21589	5/22/98	Virginia Lee	—	
	B5	EP 0848 062 A2	6/17/98	David J. Powell	—	
	B6	WO 98/26059	6/18/98	Chrysler et al.	—	
	B7	EP 0855 444 A2	7/29/99	David J. Powell	—	
	B8	WO 99/34004	8/7/99	Klaus et al.	—	
	B9	WO 99/31236	6/24/99	Bougueleret et al.	—	
	B10	WO 99/46281	9/16/99	Wood et al.	—	
	B11	WO 99/64587	12/16/99	Rholam et al.	—	
	B12	WO 00/23576	4/27/00	Hook	—	
	B13	WO 00/47618	8/17/00	Anderson et al.	—	
	B14	WO 00/58479	10/5/00	Citron et al.	—	
	B15	WO 00/56871	9/28/00	Postina	—	
	B16	WO 00/68266	11/16/00	Becker et al.	—	
	B17	WO 00/69262	11/23/00	Zhong et al.	—	
	B18	WO 01/00663	1/4/01	Tang et al.	—	
	B19	WO 01/00665	1/4/01	Tang et al.	—	
	B20	WO 01/29563	4/26/01	Christie et al.	—	
	B21	WO 01/31054	5/3/01	Christie et al.	—	
	B22	WO 01/36600	5/25/01	Zhu et al.	—	
CGN	B23	WO 01/38487	5/31/01	Zhu et al.	—	

Examiner Signature		Date Considered	8/29/03

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	09/869,414
Filing Date	June 27, 2001
First Named Inventor	Mark Gurney
Art Unit	1647
Examiner Name	C. ~~Nicholas~~ NICHOLS
Attorney Docket Number	29915/6280M

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

[1] Applicant's unique citation designation number (optional). [2] See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
CGN	C1	CHYUNG et al. Novel β-Secretase Cleavage of β-Amyloid Precursor Protein in the Endoplasmic Reticulum/Intermediate Compartment of NT2N Cells, *Journal of Cell Biology*, 138: 671-680 (August 11, 1997).	
	C2	EVIN et al., Alzheimer's disease amyloid precursor protein (AβPP): proteolytic processing, secretases and βA4 amyloid production, *Amyloid; Int. J. Exp. Clin. Invest.* 1: 263-280 (September 8, 1994).	
	C3	HAASS et al., Amyloid β-peptide is Produced by Cultured Cells During Normal Metabolism, *Nature,* 359: 322-325 (September 24, 1992).	
	C4	HAASS et al., β-Amyloid Peptide and 3-kDa Fragment are Derived by Distinct Cellular Mechanisms, *Journal of Biochemistry,* 268: 3021-3024 (February 15, 1993).	
	C5	HAASS et al., The Swedish Mutation Causes Early-Onset Alzheimer's Disease by β- Secretase Cleavage Within the Secretory Pathway, *Nature Medicine,* 12: 1291-1296 (December 1995).	
	C6	HIROSAWA et al., Characterization of cDNA Clones Selected by the GeneMark Analysis from Size-Fractionated cDNA Libraries From Human Brain, *DNA Res.*, 6(5): 329-336 (October 29, 1999).	
	C7	HUSSAIN et al., Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase, *Molecular and Cellular Neuroscience,* 14: 419-427 (1999).	
	C8	KANG et al., The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor, *Nature*, 325: 733-736 (February 19, 1987).	
	C9	KITAGUCHI et al., Novel Precursor of Alzheimer's Disease Amyloid Protein Shows Protease Inhibitory Activity, *Nature*, 331: 530-532 (February 11, 1988).	
	C10	KNOPS et al., Cell-type and Amyloid Precursor Protein-type Specific Inhibition of Aβ Release by Bafilomycin A1, a Selective Inhibitor of Vacuolar ATPases, *Journal of Biological Chemistry,* 270: 2419-2422 (February 10, 1995).	
	C11	KOO and SQUAZZO Evidence that Production and Release of Amyloid β-Protein Involves the Endocytic Pathway, *Journal of Biological Chemistry,* 269: 17386-17389 (July 1, 1994).	
CGN	C12	PONTE et al., A New A4 Amyloid mRNA Contains a Domain Homologous to Serine Proteinase Inhibitors, *Nature*, 331: 525-527 (February 11, 1988).	

PTO/SB/08B (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	~~09/688,314~~ 09/869,414
Filing Date	Sep~~tember 22, 2000~~ 27 June 2001
First Named Inventor	Mark Gurney
Group Art Unit	1647
Examiner Name	~~Sharon Turner~~ NICHOLS
Attorney Docket Number	28341/6280NCP

CD	C13	SEUBERT et al. Secretion of β-amyloid Precursor Protein Cleaved at the Amino Terminus of the β-amyloid Peptide, *Nature*, 361: 260-263 (January 21, 1993).	—
	C14	SINHA et al., Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain, *Nature*, 402: 537-540 (December, 2 1999).	—
	C15	SZECSI, The Aspartic Proteases, *Scand. J. Clin. Lab. Invest.*, 52 (suppl. 210): 5-22 (1992).	—
	C16	TANZI et al., Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA Associated with Alzheimer's Disease, *Nature*, 331: 528-530 (February 11, 1988).	—
	C17	VASSER et al., β-secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE, *Science*, 286 (5440): 735-41 (October 22, 1999).	—
	C18	YAN et al., Membrane-anchored Aspartyl Protease with Alzheimer's Disease β-Secretase Activity, *Nature*, 402: 533-537 (December 2, 1999).	—
	C19	ZHAO et al., β-Secretase Processing of the β-Amyloid Precursor Protein in Transgenic Mice Is Efficient in Neurons but Inefficient in Astrocytes, *Journal of Biological Chemistry*, 271: 31407-31411 (December 6, 1996).	—
	~~C20~~	~~PCT Search report for PCT/US 99/20881~~	~~—~~
	C21	MULLAN et al., A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of β-Amyloid, *Nature Genetics* 1: 345-347, (August 1992).	—
CD	C22	Elan and Pharmacia form Alzheimer's disease research collaboration in the area of Beta-Secretase, News 08/09/2000, ~~www.elancorp.com~~.	—

CONSIDERED, DO NOT PRINT.

Examiner Signature		Date Considered	8/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.